PPARG and type 2 diabetes mellitus: Moreover, troglitazone, an insulin-sensitizing drug that is prescribed for treating type 2 diabetes mellitus (192), is a synthetic PPARγ agonist that interferes with NF-κB activity and exerts its anti-inflammatory effects through the activation of PPARγ (38).